A recent randomized crossover trial evaluated the efficacy and safety of combining dapagliflozin with spironolactone versus using dapagliflozin alone in patients with heart failure with mildly reduced or preserved ejection fraction. Involving 108 participants (median age 76, 57% women), estimated glomerular filtration rate (eGFR) 72 mL/min/1.73 m2，the 12-week study found […]
A recent US clinical trial explored two strategies for reducing sedentary behavior and their effects on health in overweight or obese postmenopausal women. Over a 3-month period, 407 participants were randomly assigned to one of three groups: a control group focused on general healthy living, a group aiming to reduce […]
A Chinese prospective, randomized, parallel-group, superiority clinical trial revealed that bedtime dosing provides superior nocturnal blood pressure (BP) control and circadian rhythm improvement without compromising daytime or 24-hour BP control. The trial was conducted at 15 hospitals in China between June 2022 and April 2024 with a 12-week follow-up, compared […]
A systematic review and meta-analysis indicate that while antidepressant discontinuation is associated with a mild increase in physical symptoms, the average symptom burden does not reach the threshold for clinically significant discontinuation syndrome. Researchers examined symptoms using standardized measures such as the Discontinuation-Emergent Signs and Symptoms (DESS) scale and tracked […]
An international case–control study suggested that vascular risk factors influence stroke risk differently across age groups. The study enrolled age- and sex-matched cases of the first acute stroke and controls across 32 countries between Jan 11, 2007, and Aug 8, 2015. Participants underwent clinical assessments and provided blood and urine […]
An individual patient-data pooled analysis of the four Intensive Blood Pressure (BP) Reduction in Acute Cerebral Haemorrhage Trials (INTERACT) supports the safety and efficacy of early intensive BP-lowering in intracerebral hemorrhage. There were 404 patients in INTERACT1, 2829 in INTERACT2, 7036 in INTERACT3, and 1043 in INTERACT4, respectively. INTERACT1–3 enrolled […]